Fulcrum Therapeutics IncNASDAQ:FULC
- LAST PRICE7.2100
- TODAY'S CHANGE (%)-0.2100 (-2.8302%)
- Bid / Lots7.2200/ 4
- Ask / Lots7.9700/ 1
- Open / Previous Close7.4300 / 7.4200
- Day Range
- 52 Week Range
- Volume305,764
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FULC |
|---|---|---|
| 09:32 ET | 2799 | 7.43 |
| 09:34 ET | 200 | 7.39 |
| 09:36 ET | 100 | 7.34 |
| 09:38 ET | 300 | 7.34 |
| 09:39 ET | 100 | 7.35 |
| 09:41 ET | 801 | 7.395 |
| 09:52 ET | 700 | 7.375 |
| 09:59 ET | 200 | 7.4 |
| 10:01 ET | 2100 | 7.405 |
| 10:06 ET | 200 | 7.41 |
| 10:08 ET | 355 | 7.3953 |
| 10:10 ET | 250 | 7.43 |
| 10:12 ET | 200 | 7.425 |
| 10:14 ET | 1946 | 7.45 |
| 10:15 ET | 1543 | 7.45 |
| 10:17 ET | 600 | 7.5 |
| 10:19 ET | 100 | 7.51 |
| 10:21 ET | 1855 | 7.45 |
| 10:24 ET | 400 | 7.455 |
| 10:26 ET | 600 | 7.455 |
| 10:30 ET | 1500 | 7.47 |
| 10:32 ET | 1335 | 7.455 |
| 10:33 ET | 200 | 7.45 |
| 10:35 ET | 1094 | 7.425 |
| 10:37 ET | 600 | 7.44 |
| 10:39 ET | 700 | 7.435 |
| 10:42 ET | 100 | 7.435 |
| 10:44 ET | 4730 | 7.45 |
| 10:48 ET | 1263 | 7.455 |
| 10:51 ET | 250 | 7.44 |
| 10:53 ET | 1273 | 7.44 |
| 10:55 ET | 100 | 7.435 |
| 11:00 ET | 200 | 7.42 |
| 11:02 ET | 672 | 7.43 |
| 11:04 ET | 500 | 7.43 |
| 11:06 ET | 1319 | 7.445 |
| 11:08 ET | 1213 | 7.46 |
| 11:09 ET | 400 | 7.4581 |
| 11:11 ET | 762 | 7.48 |
| 11:13 ET | 2200 | 7.47 |
| 11:15 ET | 100 | 7.47 |
| 11:18 ET | 950 | 7.47 |
| 11:20 ET | 500 | 7.4795 |
| 11:22 ET | 100 | 7.47 |
| 11:24 ET | 300 | 7.47 |
| 11:26 ET | 200 | 7.46 |
| 11:27 ET | 200 | 7.47 |
| 11:29 ET | 100 | 7.47 |
| 11:31 ET | 1000 | 7.45 |
| 11:33 ET | 1132 | 7.46 |
| 11:36 ET | 400 | 7.46 |
| 11:38 ET | 850 | 7.46 |
| 11:40 ET | 1174 | 7.42 |
| 11:42 ET | 300 | 7.425 |
| 11:44 ET | 140 | 7.425 |
| 11:45 ET | 100 | 7.4175 |
| 11:47 ET | 400 | 7.41 |
| 11:49 ET | 300 | 7.42 |
| 11:51 ET | 2091 | 7.445 |
| 11:54 ET | 700 | 7.42 |
| 11:56 ET | 100 | 7.41 |
| 12:00 ET | 1117 | 7.425 |
| 12:02 ET | 230 | 7.42 |
| 12:05 ET | 100 | 7.42 |
| 12:16 ET | 300 | 7.41 |
| 12:18 ET | 839 | 7.42 |
| 12:20 ET | 700 | 7.43 |
| 12:21 ET | 675 | 7.43 |
| 12:23 ET | 2680 | 7.42 |
| 12:25 ET | 700 | 7.43 |
| 12:27 ET | 100 | 7.43 |
| 12:32 ET | 100 | 7.43 |
| 12:36 ET | 640 | 7.42 |
| 12:38 ET | 299 | 7.43 |
| 12:39 ET | 300 | 7.42 |
| 12:43 ET | 1174 | 7.43 |
| 12:50 ET | 350 | 7.44 |
| 12:56 ET | 2551 | 7.43 |
| 12:57 ET | 350 | 7.43 |
| 12:59 ET | 250 | 7.43 |
| 01:01 ET | 751 | 7.41 |
| 01:03 ET | 100 | 7.41 |
| 01:06 ET | 1579 | 7.41 |
| 01:08 ET | 800 | 7.425 |
| 01:10 ET | 1444 | 7.42 |
| 01:12 ET | 883 | 7.42 |
| 01:14 ET | 1581 | 7.43 |
| 01:15 ET | 300 | 7.44 |
| 01:17 ET | 468 | 7.441 |
| 01:26 ET | 600 | 7.44 |
| 01:28 ET | 100 | 7.445 |
| 01:32 ET | 936 | 7.44 |
| 01:33 ET | 600 | 7.425 |
| 01:35 ET | 300 | 7.425 |
| 01:37 ET | 100 | 7.425 |
| 01:39 ET | 103 | 7.425 |
| 01:42 ET | 200 | 7.425 |
| 01:44 ET | 100 | 7.425 |
| 01:50 ET | 1550 | 7.4 |
| 01:53 ET | 3730 | 7.39 |
| 01:55 ET | 2192 | 7.4 |
| 02:00 ET | 100 | 7.4 |
| 02:02 ET | 400 | 7.4 |
| 02:04 ET | 2000 | 7.38 |
| 02:06 ET | 500 | 7.36 |
| 02:08 ET | 842 | 7.3605 |
| 02:09 ET | 533 | 7.375 |
| 02:11 ET | 1375 | 7.37 |
| 02:13 ET | 100 | 7.36 |
| 02:15 ET | 1501 | 7.3683 |
| 02:18 ET | 725 | 7.37 |
| 02:20 ET | 200 | 7.37 |
| 02:22 ET | 300 | 7.36 |
| 02:24 ET | 1150 | 7.36 |
| 02:26 ET | 329 | 7.36 |
| 02:27 ET | 127 | 7.36 |
| 02:29 ET | 100 | 7.35 |
| 02:31 ET | 1104 | 7.34 |
| 02:33 ET | 5483 | 7.37 |
| 02:36 ET | 650 | 7.37 |
| 02:38 ET | 100 | 7.37 |
| 02:40 ET | 579 | 7.36 |
| 02:42 ET | 300 | 7.36 |
| 02:44 ET | 583 | 7.35 |
| 02:45 ET | 100 | 7.35 |
| 02:47 ET | 250 | 7.34 |
| 02:51 ET | 13068 | 7.31 |
| 02:58 ET | 100 | 7.32 |
| 03:00 ET | 200 | 7.31 |
| 03:02 ET | 200 | 7.3 |
| 03:03 ET | 5378 | 7.28 |
| 03:05 ET | 5676 | 7.29 |
| 03:07 ET | 100 | 7.3 |
| 03:12 ET | 600 | 7.3 |
| 03:14 ET | 1108 | 7.28 |
| 03:16 ET | 113 | 7.285 |
| 03:20 ET | 1793 | 7.29 |
| 03:21 ET | 1323 | 7.285 |
| 03:23 ET | 5568 | 7.27 |
| 03:25 ET | 200 | 7.262 |
| 03:27 ET | 693 | 7.26 |
| 03:30 ET | 1201 | 7.26 |
| 03:32 ET | 8122 | 7.235 |
| 03:34 ET | 6140 | 7.25 |
| 03:36 ET | 500 | 7.25 |
| 03:38 ET | 1164 | 7.25 |
| 03:39 ET | 750 | 7.26 |
| 03:41 ET | 1958 | 7.25 |
| 03:43 ET | 4124 | 7.26 |
| 03:45 ET | 1210 | 7.24 |
| 03:48 ET | 2433 | 7.23 |
| 03:50 ET | 949 | 7.225 |
| 03:52 ET | 4450 | 7.235 |
| 03:56 ET | 2269 | 7.21 |
| 03:57 ET | 6225 | 7.2 |
| 03:59 ET | 30804 | 7.21 |
May 20, 2024
DJ Fulcrum Therapeutics Initiated at Overweight by Cantor Fitzgerald, from 7:56AM ET on Monday May 20, 2024 by Dow Jones
7:56AM ET on Monday May 20, 2024 by Dow Jones
May 14, 2024
DJ Fulcrum Therapeutics Raised to Buy From Neutral by Goldman Sachs, from 8:50AM ET on Tuesday May 14, 2024 by Dow Jones
8:50AM ET on Tuesday May 14, 2024 by Dow JonesDJ Fulcrum Therapeutics Price Target Maintained With a $17.00/Share by HC Wainwright & Co., from 7:20AM ET on Tuesday May 14, 2024 by Dow Jones
7:20AM ET on Tuesday May 14, 2024 by Dow JonesDJ Fulcrum Therapeutics Is Maintained at Outperform by Oppenheimer, from 5:31AM ET on Tuesday May 14, 2024 by Dow Jones
5:31AM ET on Tuesday May 14, 2024 by Dow Jones
May 13, 2024
DJ Fulcrum Therapeutics Raised to Buy From Neutral by Goldman Sachs, from 4:32PM ET on Monday May 13, 2024 by Dow Jones
4:32PM ET on Monday May 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Fulcrum Therapeutics Inc | 461.2M | -4.5x | --- |
Nkarta Inc | 460.9M | -2.7x | --- |
PepGen Inc | 461.6M | -4.5x | --- |
Ocugen Inc | 458.0M | -7.5x | --- |
Adlai Nortye Ltd | 443.9M | -1.4x | --- |
Kalvista Pharmaceuticals Inc | 476.3M | -3.6x | --- |
Company Information
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.
Contact Information
- Headquarters
- 26 Landsdowne StreetCAMBRIDGE, MA, United States 02139
- Phone
- 617-651-8851
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Kate Haviland
- President, Chief Executive Officer, Director
- Alex Sapir
- Chief Financial Officer, Treasurer
- Alan Musso
- Executive Vice President - Patient Affairs
- Mel Hayes
- Chief Medical Officer
- Patrick Horn
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $461.2M |
|---|---|
Revenue (TTM) | $2.5M |
Shares Outstanding | 62.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.32 |
EPS | $-1.61 |
Book Value | $3.80 |
P/E Ratio | -4.5x |
Price/Sales (TTM) | 183.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -4,484.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
